147 results about "Myelin sheaths" patented technology

The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.

The invention discloses an IL7R gene-deleted zebra fish mutant and a preparation method thereof. The construction of the IL7R gene-deleted zebra fish mutant is realized through a CRISPR / Cas9 technology. Moreover, the invention also discloses application of the IL7R gene-deleted zebra fish mutant; a mutant model provided by the invention can be used for studying an effect of IL7R in the nervous system development and myelination.

A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.

This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and / or treatment of demyelination disorders.

The invention discloses a new kind of nerve allotransplant, the preparation method and its medical application. The invention employs chemical extraction method to remove the schwann cell, axon and myelin sheath that can cause rejection for nerve allotransplant, stores stroma cell and three-dimensional pipeline structure for axon regeneration, and provides intact regenerative frame. The physical and biochemical property of nerve allotransplant are similar to that of normal nerve, and can be used as nerve allotransplant for damaged nerve.

A method for treatment of multiple sclerosis and related disease states. A histamine H2 mimicking agent is administered in an amount which is effective to stimulate production of a cyclic AMP in the body. A phosphodiesterase inhibitor is administered in conjunction with the histamine H2 mimicking agent to conserve the cyclic AMP which is thus produced. It is believed that the increased cyclic AMP levels serve to maintain the patient's myelin against self degeneration. The histamine H2 mimicking agent may be histamine phosphate and the phosphodiesterase inhibitor may be caffeine. The histamine H2 mimicking agent and the phosphodiesterase inhibitor may be mixed in a gel and administered using a transdermal patch.

The invention discloses transgenic zebrafish with specific myelin sheath removal capacity as well as a preparation method and an application thereof. The preparation method comprises the following steps: recombinant plasmid mbp-nfsB-EGFP and a Tol 2 transposase mRNA (messenger ribonucleic acid) are jointly introduced into wild zebrafish; and a zebrafish strain with stable inheritance is cultured and obtained, and the zebrafish strain with stable inheritance is the transgenic zebrafish with specific myelin sheath removal capacity, wherein the nucleotide sequence of an mbp gene promoter carried in the recombinant plasmid mbp-nfsB-EGFP is represented as SEQ ID NO.1. With adoption of the method, the transgenic zebrafish which can specifically remove myelin sheath, cause myelinoclasis and has stable inheritance capacity can be prepared and obtained effectively, under the action of metronidazole, oligodendrocyte of juvenile transgenic zebrafish can be removed specifically and the juvenile transgenic zebrafish has pathologic change of myelinoclasis together with decreased motor function, therefore, the transgenic zebrafish can provide a forceful animal model for a regulatory mechanism for viviperception of myelin sheath damage and regeneration and related drug screening.

The invention belongs to the field of traditional Chinese medicaments and relates to a compound preparation for promoting neuromuscular regeneration and a preparation method thereof. The compound preparation is prepared from raw material medicaments, such as codonopsis pilosula, astragalus, root of red-rooted salvia and the like, and medicinally acceptable auxiliary materials or auxiliary ingredients according to a specific weight ratio by a water extraction method. The result of a pharmacological test shows that the compound preparation can increase GAP-43 expression in early damaged nerve, can be competitively combined to a G protein reaction site, can promote quick growth of axon and can contribute to reconstruction of synapse. The result of an animal test shows that the compound preparation promotes metabolism of an organism, increases blood supply of a damaged part, eliminates degenerated myelin sheath, promotes fission and proliferation of Schwann cells and has obvious effect of accelerating regeneration of peripheral nerves after the peripheral nerves are damaged. The compound preparation can be further prepared into a medicament clinically used for promoting neuromuscular regeneration so as to bring benefit to more patients suffered from nerve injury.

The present invention relates to methods and formulations for GAD- vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a primeand boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. The present invention relates to medications and methods for treatment of autoimmune disease within six months from diagnosis.

The invention relates to a modified rat accellular spinal cord bracket material and a preparation method thereof. With the preparation method, the spinal cord accellular technology is optimized; chemical crosslinking treatment is improved; a material prepared by the method has a relatively complete three-dimensional mesh structure, structure stability and relatively high enzymolysis resistance; on the basis of removing cells and myelin sheath components in a spinal cord, the material effectively retains extracellular matrix and has highly-simulated three-dimensional mesh structure and high porosity; the immunogenicity is weak; the cell compatibility, the biological compatibility and the biological safety are high; equipotential transplantation and dissection transplantation are conveniently realized in in-vivo transplantation; and the modified rat accellular spinal cord bracket material is suitable for reparation, reconstruction and research of the spinal cord.

The invention discloses a health-care product for supplying brain nutrition, which is characterized by comprising the following components in parts by weight: 25-30 parts of pine nut oil, 15-20 parts of oryzanol, 15-20 parts of rice germ oil, 5-10 parts of linoleic acid, 5-10 parts of camellia seed oil, 5-10 parts of hickory oil, and 5-10 parts of a-linolenic acid. The health-care product for supplying brain nutrition disclosed by the invention is capable of nourishing cranial nerves, cells and myelin sheaths, repairing brain nerves and cells, delaying cell senescence, making brain healthy, being beneficial to intelligence, improving memory, promoting overall development of brain and relieving mental disorders and senile diseases, such as mental diseases, depression, hyperactivity, phobia, infantile autism and senile dementia and is applied to all people.

The invention discloses a method for preparing a novel magneto-induction degradable nervous tissue engineering material. The technical scheme of the method is carried out in the following steps: 1, preparing magnetic nanoparticles MNPs; 2, preparing a magnetic gel-shaped turbid liquid; 3, preparing a nervous tissue engineering material; and 4, carrying out crosslinking disinfection treatment. According to the magneto-induction degradable nervous tissue engineering material prepared by the method, a generated nerve grows in an oriented manner by the magnetic field inside the tissue material to accelerate repairing and the forming of myelin sheath, and the effect of repairing nerve defect can be further improved.

The invention discloses a superparamagnetic iron oxide nano-particle-collagen-chitosan magnetic degradable nerve conduit and a preparation method thereof. The preparation method comprises the steps of (1) preparing SPIONs (Superparamagnetic Iron Oxide Nano-particles); (2) preparing an SPIONs-collagen-chitosan magnetic degradable nerve conduit; and (3) carrying out disinfection treatment. With the adoption of the preparation method, in the process of preparing the superparamagnetic iron oxide nano-particle-collagen-chitosan magnetic degradable nerve conduit, as superparamagnetic iron oxide nano-particles with a certain concentration are adopted to form a magnetizable magnetic system, regenerated nerves can be guided to carry out orientated growth, the secretion of nerve nutrient substances can also be promoted, and damaged nerves can be more effectively promoted to regenerate. With the adoption of the prepared nerve conduit, the regenerated nerves can carry out orientated growth and accelerated repair to compound a myelin sheath by virtue of an internal magnetic field of the conduit and can be used for further improving the repair effect in nerve defect.

The present invention relates to pharmaceutical compositions comprising glandular kallikrein in combination with myelin basic protein or copaxone for use in the treatment of multiple sclerosis. The present invention further relates to a method of suppressing autoimmune responses in a patient afflicted with or suffering at least one clinical sign of multiple sclerosis, comprising administering to said patient a therapeutically effective amount of glandular kallikrein in combination with a therapeutically effective amount of myelin basic protein or copaxone.

The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).

Methods and devices are provided for activating brown adipose tissue (BAT) using electrical energy. In general, the methods and devices can facilitate activation of BAT to increase thermogenesis. The BAT can be activated by applying an electrical signal thereto that can be configured to target sympathetic nerves that can directly innervate the BAT. The electrical signal can be configured to target the sympathetic nerves using fiber diameter selectivity. In other words, the electrical signal can be configured to activate nerve fibers having a first diameter without activating nerve fibers having diameters different than the first diameter. Sympathetic nerves include postganglionic unmyelinated, small diameter fibers, while parasympathetic nerves that can directly innervate BAT include preganglionic myelinated, larger diameter fibers. The electrical signal can be configured to target and activate the postganglionic unmyelinated, small diameter fibers without activating the preganglionic myelinated, larger diameter fibers.

A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering an effective amount of a MAG antagonist or anti-MAG antibody including altered antibodies and functional fragments thereof.

The invention provides a purpose of a tetrahedral frame nucleic acid in a medicine for treating demyelinating diseases, including multiple sclerosis. The tetrahedral frame nucleic acid is formed in a way that four single-stranded DNAs are subjected to complementary base pairing, and the sequences of the four single-stranded DNAs are independently selected from the sequences of SEQ ID NO.1-4 one by one. The tetrahedral frame nucleic acid can inhibit cell apoptosis of the central nervous system and recover expression of a myelin-associated protein so as to quicken re-myelination and increase an amount of myelinated axons. Therefore, the tetrahedral frame nucleic acid can effectively treat the demyelinating disease, especially the multiple sclerosis, and has an excellent clinical application prospect.

Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.

The invention discloses a method for preparing a collagen material used for repairing peripheral nerve injury. The preparation method provided by the invention comprises the following steps: co-incubating vascular endothelial growth factors (VEGF) with collagen binding domains and an ordered collagen material, so as to obtain the collagen material used for repairing peripheral nerve injury. Experiment results show that the collagen material containing VEGF-CBD factors and used for repairing peripheral nerve injury can promote peripheral nerve regeneration, as well as exponential recovery of impaired peripheral nerve functions, electrophysiological recovery of peripheral nerve transaction parts, expression of S-100 proteins and / or neurofilament proteins of peripheral nerve injured parts, increase of diameter and / or wall thickness of myelin sheaths of the peripheral nerve injured parts and recovery of target organs, which proves that the functional material has more practical guiding significance on future clinical application to peripheral nerve injury repairing.

The invention discloses a feed additive for reducing the cholesterol content in eggs and a preparation method thereof. Cholesterol has an important physiological function in animal body, is an important component of various mode structures of cells and nerve myelin sheath, and is a precursor for synthesizing bile, steroid hormone and vitamin D3; however, excessively high cholesterol concentration in blood causes high blood fat and a series of consequent cardiovascular diseases such as atherosclerosis, high blood pressure, coronary heart disease and the like. The feed additive disclosed by the invention comprises the following components in parts by weight: 16.35-18.25 parts of curcumin, 0.02-0.03 part of brochantite, 12.36-15.85 parts of hawthorn, 22.35-25.68 parts of safflower seed oil and 42.00-46.00 parts of natural red yeast rice. The feed additive disclosed by the invention is used for reducing the cholesterol content in eggs.

The invention relates to a composite stem cell bionic nerve conduit. The composite stem cell bionic nerve conduit comprises a braided hose side wall; a round hose is formed via coiling of the braided hose side wall; and gel and stem cells are arranged in the round hose formed via coiling of the braided hose side wall. The materials of the composite stem cell bionic nerve conduit are high-molecular degradable materials, are easily available, and possesses certain strength and excellent biocompatibility; the nerve conduit side wall formed via braiding possesses a lot of pores with the same directivity; the compactness of the nerve conduit side wall can be adjusted via different braiding methods, so that it is beneficial for nutrient delivery and exchanging; atmospheric pressure plasma jet processing is capable of increasing nerve conduit braided fiber surface area, and improving conduit hydrophilic performance and cellular affinity; the gel in the nerve conduit is semi-solidified, a support interface and a material exchange interface are formed by the semi-solidified gel, so that it is beneficial for uniform distribution of stem cell in the nerve conduit, and cell fixing and differentiation, and it is also beneficial for growth of regenerated nerve axon and formation of myelin sheath, and repairing of long nerve.

The invention discloses application of shikimic acid in preparing a drug for preventing or treating demyelinating diseases. In studying the effect of the shikimic acid in preventing or treating the demyelinating diseases, it is found that the shikimic acid can alleviate the severity of an inflammatory mouse demyelinating disease model induced by myelin sheath oligodendrocyte glycoprotein, improvethe demyelination lesion conditions of a focal mouse spinal cord demyelinating model induced by lysoph-osphatidylcholine, and accelerate remyelination and reduce the demyelination size by promoting oligodendrocyte progenitor cells to be differentiated into mature oligodendrocytes. As is shown by all above, the shikimic acid has a great application prospect in clinical treatment of the demyelinating diseases.

Methods are provided for decreasing inflammatory disease in a subject by administering an effective dose of a lipid, fatty acid, or analog thereof.

A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and / or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.

Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.

The invention discloses a diabetic peripheral neuropathy treatment medicine and a manufacturing method thereof. The medicine is mainly prepared from radix astragali, radix rehmanniae, rhizoma dioscoreae, angelica sinensis, cornus officinalis, cassia twig, salvia miltiorrhiza, lumbricus and leech. The medicine has efficacies of Qi tonifying, Yin nourishing, kidney tonifying, blood circulation promoting, stasis removing and meridian activating and has functions of reducing blood glucose, increasing microvascular diameter and blood flow volume, increasing sciatic nerve conduction velocity and increasing sural nerve tract area, myelin sheath fiber number and myelin sheath fiber density. The medicine can be used for treatment of diabetic peripheral neuropathy and has advantages of remarkable curative effects, quick action, short treatment period, safety and avoidance of relapse and side effects.

Methods and devices are provided for activating brown adipose tissue (BAT) using electrical energy. In general, the methods and devices can facilitate activation of BAT to increase thermogenesis. The BAT can be activated by applying an electrical signal thereto that can be configured to target sympathetic nerves that can directly innervate the BAT. The electrical signal can be configured to target the sympathetic nerves using fiber diameter selectivity. In other words, the electrical signal can be configured to activate nerve fibers having a first diameter without activating nerve fibers having diameters different than the first diameter. Sympathetic nerves include postganglionic unmyelinated, small diameter fibers, while parasympathetic nerves that can directly innervate BAT include preganglionic myelinated, larger diameter fibers. The electrical signal can be configured to target and activate the postganglionic unmyelinated, small diameter fibers without activating the preganglionic myelinated, larger diameter fibers.

The invention discloses an acellular nerve graft which is an acellular heterogeneous nerve scaffold and contains a well-preserved three-dimensional orientation structure, which can guide nerve regeneration, of a nerve fiber nerve basilar membrane vessel. The structure has the components of cells, myelin sheaths, axons and fat that cause immunoreaction removed. The invention also discloses a preparation method of the acellular nerve graft, wherein the preparation method includes the steps: obtaining mammalian peripheral nerves under an aseptic condition, and stripping and removing fat and connective tissues around nerves under the aseptic condition; freezing and thawing the treated nerves repeatedly, carrying out decellularization by a chemical extraction and ultrasound combined method, cleaning with normal saline and adding deoxyribonuclease and ribonuclease solutions, and thus obtaining an initial acellular nerve graft; and freezing and drying the initial acellular nerve graft, then carrying out fat extraction treatment with supercritical carbon dioxide, and carrying out sterilization treatment to obtain the acellular nerve graft.

The present invention disclosed methods of inducing maturation of oligodendrocyte cells. A method of inducing myelination in a patient suffering from demyelination is also disclosed